Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.52 |
| ▸ | CCR1 | P32246 | 2/20 | 0.46 |
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | CCR8 | P51685 | 2/20 | 0.46 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599103 | 0.83 | CYP1A2 (0.68) | TSHRCYP1A2CYP2A6CCR1CCR5 | |
| SCHEMBL598952 | 0.81 | CYP1A2 (0.65) | TSHRCYP1A2CYP2A6CCR1CCR5 | |
| SCHEMBL5494672 | 0.79 | TSHR (0.45) | TSHRCYP1A2CYP2A6TDP2NSD2 | |
| SCHEMBL37955 | 0.79 | TSHR (0.45) | TSHRCYP1A2CYP2A6TDP2NSD2 | |
| SCHEMBL10626178 | 0.79 | TSHR (0.46) | TSHRCYP1A2CYP2A6CCR1CCR5 | |
| SCHEMBL18892552 | 0.79 | CYP1A2 (0.38) | TSHRCYP1A2CYP2A6CCR1CCR5 | |
| SCHEMBL20356137 | 0.79 | CYP1A2 (0.38) | TSHRCYP1A2CYP2A6CCR1CCR5 | |
| SCHEMBL31747510 | 0.77 | TSHR (0.78) | TSHRCYP1A2CYP2A6PAX8HPGD | |
| SCHEMBL21127529 | 0.77 | CYP2A6 (0.43) | TSHRCYP1A2CYP2A6CCR1CCR5 | |
| SCHEMBL458566 | 0.77 | TSHR (0.78) | TSHRCYP1A2CYP2A6PAX8HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5117202-A | — | — | None | — | — | JP | disclosed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| CN-102066306-A | Process for producing aromatic polycarboxylic acid | DAICEL CHEM | 2011-05-18 | — | — | CN | disclosed |
| US-20110071314-A1 | PROCESS FOR PRODUCING AROMATIC POLYCARBOXYLIC ACID | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2011-03-24 | — | — | US | disclosed |
| US-RE42015-E1 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1569652-A4 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
| US-7105527-B2 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2006-09-12 | — | — | US | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| JP-H05117202-A | PRODUCTION OF 1,2,5,6-NAPHTHALENETETRACARBOXYLIC ACID | COSMO SOGO KENKYUSHO:KK | 1993-05-14 | — | — | JP | disclosed |
| US-4599445-A | Process for benzophenone tetracarboxylic acid | THE DOW CHEMICAL COMPANY (US) | 1986-07-08 | — | — | US | disclosed |
| US-4562271-A | Preparation of 3-alkanoyloxyphthalides | THE UPJOHN COMPANY (US) | 1985-12-31 | — | — | US | disclosed |
| US-4485247-A | 3-Alkanoyloxyphthalides | THE UPJOHN COMPANY (US) | 1984-11-27 | — | — | US | disclosed |
| EP-0125342-A1 | Process for preparation of aromatic polycarboxylic acids and intermediates therefor | THE UPJOHN COMPANY (US) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | TSHR 4176/4885CYP1A2 1240/4885CYP2A6 1327/4885 |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, NT5C3B, PNP | TSHR 4434/4885CYP1A2 1415/4885CYP2A6 1388/4885 |
| US-20110071314-A1 | PROCESS FOR PRODUCING AROMATIC POLYCARBOXYLIC ACID | DDC, SCO2, OAT | TSHR 3031/4885CYP1A2 360/4885CYP2A6 2697/4885 |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | TSHR 4374/4885CYP1A2 810/4885CYP2A6 1101/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | TSHR 3766/4885CYP1A2 592/4885CYP2A6 1024/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | TSHR 4165/4885CYP1A2 1174/4885CYP2A6 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.